## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-10.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($19.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Norges Bank Buys Shares of 913,407 Sarepta Therapeutics, Inc. $SRPT**
- Source: MarketBeat | 20251209T110905 | Neutral | Relevance: 99%
-  Norges Bank has acquired a new position of 913,407 shares in Sarepta Therapeutics, valued at approximately $15.62 million, representing about 0.93% of the company. Institutional investors collectively own roughly 86.68% of SRPT. Despite a consensus "Hold" rating from analysts and a missed EPS target in the latest quarter, the company's revenue exceeded expectations.

**2. Sarepta Therapeutics grants $12 million equity award to CEO Douglas Ingram**
- Source: Investing.com | 20251208T130939 | Somewhat-Bullish | Relevance: 99%
-  Sarepta Therapeutics' Board of Directors granted CEO Douglas S. Ingram a $12 million equity award, his first since 2017. Half of the award consists of time-based restricted stock units vesting over three years, while the other half is performance-based, tied to Sareptaâ€™s Incentive EBITDA over a two-year period. This award is detailed in an SEC filing and reflects the company's ongoing compensation strategy.

**3. Sarepta Therapeutics (SRPT) Is Up 6.8% After FDA Clears Cohort 8 Dosing in ENDEAVOR Trial**
- Source: Simply Wall Street | 20251209T100905 | Neutral | Relevance: 99%
-  Sarepta Therapeutics saw a 6.8% stock increase after the FDA approved dosing in Cohort 8 of its ENDEAVOR trial for ELEVIDYS in non-ambulant Duchenne muscular dystrophy patients. This regulatory step is crucial for expanding ELEVIDYS's use beyond ambulant patients while managing safety concerns like liver injury. The company faces an investment narrative challenged by these safety concerns, impacting uptake and revenue timing, but the Cohort 8 approval offers a positive direction for label expansion efforts.

**4. Sarepta a new outperform at Wedbush as selloff overdone**
- Source: Seeking Alpha | 20251209T160905 | Bullish | Relevance: 98%
- Wedbush initiated coverage on Sarepta Therapeutics (SRPT) with an Outperform rating. The firm believes the selloff, which occurred earlier this year following the deaths of two boys on one of its Duchenne muscular dystrophy gene therapies, is overdone. Wedbush has set a $32 price target for SRPT.

**5. Sarepta Therapeutics Gets A Vote Of Confidence After Sell-Off**
- Source: Finimize | 20251209T170905 | Bullish | Relevance: 98%
-  Sarepta Therapeutics saw its shares rise after Wedbush issued an 'outperform' rating and a $32 price target, deeming the recent sell-off an overreaction. Despite setbacks with its gene therapy Elevidys, Wedbush sees recovery potential, citing strong sales from existing treatments and potential regulatory expansion. The biotech's resilience and the market's reaction highlight the unpredictable nature of innovation in the industry.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 106.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Tudor Investment Cor: 65.7% (+135261.8%)
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (19.9%, 3.1 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 36.5% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 19.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.7 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 12.3% to 2.1% (-10.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.6%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 5.6pp, stock-specific strength. Below SMA200 (0.64x), long-term trend not supportive. RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.12% (CS: 70) | Neutral |
| RSI_14 | 58.3 | Neutral |
| MACD Histogram | 0.42 | Bullish |
| vs SMA20 | 1.127x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 0.635x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $22.20
- **Stop Loss:** $19.40 (12.6% risk)
- **Target:** $25.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 178
- **Position Value:** $3,951.60
- **Portfolio %:** 3.95%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*